BridgeBio Pharma Inc.
BridgeBio Reports Q4 and Full Year 2025 Financial Results
Summary
BridgeBio Pharma, Inc. reported its financial results for Q4 and the full year 2025, posting $154.2 million in Q4 revenues and $502.1 million for the full year. Attruby, their lead drug for transthyretin amyloid cardiomyopathy (ATTR-CM), achieved significant milestones, including FDA approval and commercial success with over 7,800 patient prescriptions. The company also provided positive updates on its pipeline, with key trials for drugs targeting other genetic conditions showing promising results. Despite strong revenue growth, BridgeBio reported a net loss of $192.9 million for Q4 and $724.9 million for the full year.
Profitelligence Alerts
Get alerts for BBIO
Be first to know when BridgeBio Pharma Inc. files with the SEC.
Filing Categories
Advertisement
About BridgeBio Pharma Inc.
BridgeBio Pharma Inc. is a cutting-edge biotechnology company focused on discovering, developing, and delivering transformative medicines for patients with genetic diseases. The company's primary purpose is to bridge the gap in medical research and bring breakthrough therapies to those with rare and often overlooked genetic disorders. By utilizing a targeted approach, BridgeBio Pharma Inc. works across multiple sectors including dermatology, oncology, cardiology, neurology, and endocrinology. The company partners with academic institutions, research organizations, and industry leaders to harness the latest scientific advancements in genomics and biotechnology. Established with a mission to translate genetic research into real-world medical solutions, BridgeBio Pharma Inc. plays a significant role in the biopharmaceutical market. It is heavily involved in the early and late stages of drug development, positioning itself as a key player in the quest to address unmet medical needs. This focus on genetic-centric therapies underlines its importance in the rapidly evolving landscape of biotechnology and personalized medicine.
Official SEC Documents
Advertisement